Introduction: In France, hepatitis C is five times more common in prisons than in the general population. Treatment with direct-acting antivirals (DAAs) has been available to all prisoners since 2014. There were no recent data on hepatitis management practices in prisons. Objective: To establish a national overview of diagnostic and therapeutic practices for hepatitis C among the prison population in France in 2015. Methodology: A self-report survey conducted via email among the 168 prison health units (USMPs) providing care to inmates. Results: Among the USMPs, 64 (38%) participated in this survey, representing 39% of the prison population. Screening was performed for 70% of inmates, with results routinely reported in 72% of USMPs. Non-invasive methods for assessing liver fibrosis were performed in 84% of the USMPs, and 56% of the USMPs had access to on-site specialist consultations; 66% of the USMPs initiated at least one DAA treatment in 2015, and 130 patients were treated. A therapeutic education program was in place in 16% of the USMPs. Discussion and conclusion: the management of hepatitis C in prisons in France is being organized despite prison and healthcare constraints and disparities among the USMPs.